Anti-addiction Therapies, 2006-2011 - The Pharmaceutical Industry’s Next Viagra?

More money is spent advertising alcohol than any other product. For some, it like gambling and cigerettes are pleasant distractions, yet for others they are the generators of unbearable cravings and the cause of considerable distress. For them their addition is a disease. According to a new report by visiongain - Anti-addiction Therapies, 2006-2011 - society is crying out for solutions. Which pharmaceutical companies are now aiming to be that cure? This report will tell you.

Doctors and concerned specialists have long maintained a behavioural-based approach to treating addiction is the most effective treatment programme. Suggested pharmaceutical solutions simply did not work. That is it seems…until now. Two leading pharmaceutical companies have developed novel drugs that could revolutionise the treatment of obesity and nicotine addiction. And what is more, those drugs could save health authorities millions of dollars. With the pharmaceutical industry anxiously seeking the next blockbuster product, it is hardly surprising that Chantix and Acomplia are generating so much interest. Are these drugs set to shift the focus of the pharmaceutical industry? Find out today.

Will these drugs really make much of a difference for such complex disorders? Is this not just the industry wary of decline seizing an opportunity to make money? Visiongain’s report – Anti-addiction Therapies, 2006-2011 – assesses the currently available drugs, analysing which pipeline drugs appear to fit unmet needs best. This report also examines which pharmaceutical companies are likely to be market leaders by 2011.

Pfizer’s Chantix, for the treatment of nicotine addiction, and Sanofi-Aventis’ Acomplia might provide not only much needed effective relief to thousands of addicts, but could also help develop and drive a market as Viagra did for erectile dysfunction. Markets that are currently worth $1 billion could multiply several-fold within the foreseeable future.

“If Chantix and Acomplia prove to be as effective, but with the minimal side effect profiles that Pfizer and Sanofi-Aventis claim, then we could see significant development in these treatment markets,” commented visiongain market analyst and author of this latest report, Tristan Heath. This optimism is based upon the increasing incidence of obesity throughout the developed world and the stated wish of 70% of smokers to quit tobacco. Health authorities throughout the developed world have placed these health issues as top priorities. This is a potential market you cannot afford to ignore. Imagine the potential success your company could aachieve through being informed of this market now.

Treatment can be tailored to the individual and typically involve a combination of drug and behavioural therapy. Treatment of drug addiction is usually a long, multi-stage process. Encouragingly, modern drug-dependency treatment regimes are generally believed to be effective, with 40-70% of patients successfully recovering from their addiction. Can that same success be repeated in other addictions. Find out now by simply placing your order for this business critical report.

What is in the report?

- Statistics of addiction, including potential patient populations and the economic burden of addiction.

- Drug addiction – Heroin and cocaine addiction treatments, including the development of vaccinations for cocaine addiction.

- Alcohol addiction – A review of the new products for the treatment of alcohol addiction, largely those that have been indicated for the treatment of depression or opioid addiction.

- Smoking addiction – Potentially a huge market. Many health authorities have placed smoking as a priority. Pfizer have recently launched Chantix, which is likely to be the first specific treatment for smoking that is an alternative to the nicotine replacement.

- Gambling addiction – A market that is more potential than current reality. It faces difficulties in both developing effective treatments and overcoming cultural perception that gambling is not something that should necessarily be treated by a pharmaceutical.

- Obesity treatment – Potentially the largest market. The prevalence of obesity is increasing, with Sanofi-Aventis having recently launched Acomplia.

- Pipeline products – The interest in the addiction markets stems from the potentially large patient populations and also the large number of products in the pipeline.

- World market by country region for the specific treatment markets. Specific drivers and restraints for the addiction treatment markets are considered.

- Unique research and primary information unavailable elsewhere

Why you must by this report:

The pharmaceutical industry has been seeking the next blockbuster drug, yet it appears as though these might not be as profligate as they have been in the past. However, the addiction treatment markets hold promise, particularly for the development of products for nicotine addiction and the treatment of obesity. This report analyses the current situation in the market and assesses the potential of the products that are currently in the development pipeline. A comprehensive analysis of the addiction treatment market from 2006-2011 outlines the potential of the market. Visiongain expects to see the development of at least two multi-billion dollar markets. You and your company should be part of this market, and you could be by placing your order immediately.

Unique benefits to you when you order this report:

- Full searchable report when you buy the company or corporate editions

- Immediate access through our exclusive Reading Room

- You can access your report whichever country you are in without using harddrive space

- Primary research throughout. You will not find this information anywhere else

- Report stored in your reading room for ever

- Copies can be printed off for offline reading

- Packed with charts, analysis, figures, graphs and tables

If you buy one report this year make sure it is the report that will guarantee your success for the forthcoming years. Order this report now.

Lead Analyst: Tristan Heath Publication Date: 19/10/06 Pages: 126

Single user licence: The Report is delivered via an on-line reading room. One use access only, the report is in Flash format in a printable format.

Department: Report is delivered via an on line reading room. Five user access only, the report is in Flash format in a printable format.

Company/site wide licence: The report is delivered in email format as a PDF document with no locking system attached. The report can be loaded onto the company's intranet site.
Table of Contents

Price
Single User Licence $2998.00
Department Licence 5 Users $5998.00
Company-wide Intranet Licence $9998.00